Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-blind, Randomized, Placebo-controlled Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Multiple Doses of UCB4940 Administered as Add-on to Certolizumab Pegol Therapy in Subjects With Moderate-to-Severe Rheumatoid Arthritis

Next Previous
Search
Trial Profile

A Double-blind, Randomized, Placebo-controlled Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Multiple Doses of UCB4940 Administered as Add-on to Certolizumab Pegol Therapy in Subjects With Moderate-to-Severe Rheumatoid Arthritis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 11 Apr 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bimekizumab (Primary) ; Certolizumab pegol
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors UCB

Most Recent Events

  • 18 Jun 2019 Georgia was a planned location as per European Clinical Trials Database.
  • 08 Jun 2019 Primary endpoint has been met. (Change from Baseline 2 in DAS28(CRP)), as per results published in the Annals of the Rheumatic Diseases.
  • 08 Jun 2019 Results evlatuating the safety and efficacy of dual neutralisation of interleukin (IL)-17A and IL-17F with bimekizumab in addition to certolizumab pegol (CZP) in patients with rheumatoid arthritis and inadequate response (IR) to certolizumab pegol are published in the Annals of the Rheumatic Diseases

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top